These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37815234)

  • 1. Prior Use of Angiotensin-converting Enzyme Inhibitors or Angiotensin II Receptor Blockers and Clinical Outcomes of Sepsis and Septic Shock: A Systematic Review and Meta-analysis.
    Shrestha DB; Sedhai YR; Oli PR; Proskuriakova E; Adelkhanova A; Shtembari J; Khan TMA; Singh K; Ahmed MA; Waheed I; Kazimuddin N; Steff R; Acharya R; Patel NK
    J Cardiovasc Pharmacol; 2024 Jan; 83(1):16-22. PubMed ID: 37815234
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury.
    Suberviola B; Rodrigo E; González-Castro A; Serrano M; Heras M; Castellanos-Ortega Á
    Med Intensiva; 2017; 41(1):21-27. PubMed ID: 28341094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preadmission Antihypertensive Drug Use and Sepsis Outcome: Impact of Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin Receptor Blockers (ARBs).
    Hsieh MS; How CK; Hsieh VC; Chen PC
    Shock; 2020 Apr; 53(4):407-415. PubMed ID: 31135703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Premorbid angiotensin converting enzyme inhibitors or angiotensin II receptor blockers in patients with sepsis.
    Hasegawa D; Lee YI; Prasitlumkum N; Chopra L; Nishida K; Smith RL; Sato R
    Am J Emerg Med; 2022 Dec; 62():69-77. PubMed ID: 36270096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of and Risk Factors for Severe Adverse Events in Elderly Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers after an Acute Myocardial Infarction.
    Fang G; Annis IE; Farley JF; Mahendraratnam N; Hickson RP; Stürmer T; Robinson JG
    Pharmacotherapy; 2018 Jan; 38(1):29-41. PubMed ID: 29059475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers in diabetic nephropathy: a systematic review and meta-analysis.
    Du YH; Guan CJ; Li LY; Gan P
    Ann Palliat Med; 2022 Mar; 11(3):1093-1101. PubMed ID: 35365039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease.
    Cooper TE; Teng C; Tunnicliffe DJ; Cashmore BA; Strippoli GF
    Cochrane Database Syst Rev; 2023 Jul; 7(7):CD007751. PubMed ID: 37466151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACE Inhibitor Benefit to Kidney and Cardiovascular Outcomes for Patients with Non-Dialysis Chronic Kidney Disease Stages 3-5: A Network Meta-Analysis of Randomised Clinical Trials.
    Zhang Y; He D; Zhang W; Xing Y; Guo Y; Wang F; Jia J; Yan T; Liu Y; Lin S
    Drugs; 2020 Jun; 80(8):797-811. PubMed ID: 32333236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
    Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
    JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pre-transplantation use of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker in kidney transplant recipients-propensity score-matched analysis.
    Lee J; Jung CY; Kim H; Kim HJ; Ko Y; Kwon H; Shin S; Kim YH; Park SK; Baek CH
    J Nephrol; 2024 Jul; 37(6):1589-1597. PubMed ID: 38684638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis.
    Lee HW; Suh JK; Jang E; Lee SM
    Korean J Intern Med; 2021 Mar; 36(2):371-381. PubMed ID: 32264653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis to evaluate the clinical outcomes in COVID-19 patients on angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Grover A; Oberoi M
    Eur Heart J Cardiovasc Pharmacother; 2021 Mar; 7(2):148-157. PubMed ID: 32542337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness of Angiotensin II Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in Older Nursing Home Residents After Myocardial Infarction: A Retrospective Cohort Study.
    Zullo AR; Riester MR; Erqou S; Wu WC; Rudolph JL; Steinman MA
    Drugs Aging; 2020 Oct; 37(10):755-766. PubMed ID: 32808250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renin-Angiotensin-Aldosterone System Blockade after AKI with or without Recovery among US Veterans with Diabetic Kidney Disease.
    Murphy DP; Wolfson J; Reule S; Johansen KL; Ishani A; Drawz PE
    J Am Soc Nephrol; 2023 Oct; 34(10):1721-1732. PubMed ID: 37545022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis.
    Baral R; Tsampasian V; Debski M; Moran B; Garg P; Clark A; Vassiliou VS
    JAMA Netw Open; 2021 Mar; 4(3):e213594. PubMed ID: 33787911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renin-Angiotensin System Blockers and the Risk of COVID-19-Related Mortality in Patients with Kidney Failure.
    Soler MJ; Noordzij M; Abramowicz D; de Arriba G; Basile C; van Buren M; Covic A; Crespo M; Duivenvoorden R; Massy ZA; Ortiz A; Sanchez JE; Petridou E; Stevens K; White C; Vart P; Gansevoort RT;
    Clin J Am Soc Nephrol; 2021 Jul; 16(7):1061-1072. PubMed ID: 34088718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin converting enzyme inhibitors and angiotensin receptor blockers have no effect on the outcomes of endovascular revascularization in tibial arterial occlusive disease.
    Juneja A; Zia S; Abeysekara A; Shams S; Singh K; Schor J; Deitch J
    Vascul Pharmacol; 2020 Aug; 131():106764. PubMed ID: 32629143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Short-Term Mortality After Sepsis: A Population-Based Cohort Study.
    Hsu WT; Galm BP; Schrank G; Hsu TC; Lee SH; Park JY; Lee CC
    Hypertension; 2020 Feb; 75(2):483-491. PubMed ID: 31838905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACE inhibitors and angiotensin receptor blockers differentially alter the response to angiotensin II treatment in vasodilatory shock.
    Leisman DE; Handisides DR; Busse LW; Chappell MC; Chawla LS; Filbin MR; Goldberg MB; Ham KR; Khanna AK; Ostermann M; McCurdy MT; Adams CD; Hodges TN; Bellomo R;
    Crit Care; 2024 Apr; 28(1):130. PubMed ID: 38637829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of Sepsis and Mortality Among Patients With Chronic Obstructive Pulmonary Disease Treated With Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers.
    Lai CC; Wang YH; Wang CY; Wang HC; Yu CJ; Chen L;
    Crit Care Med; 2019 Jan; 47(1):e14-e20. PubMed ID: 30303835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.